Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma

Cancer - United States
doi 10.1002/cncr.30863
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy